Parexel IPO seeks $20.3 mil. to fund geographic expansion, possible acquisitions.
PAREXEL $20 MIL. IPO WILL FUND GEOGRAPHIC EXPANSION, NEW SERVICES, the contract research organization said in a recent registration statement for an initial public offering of 2.2 mil. shares. Waltham, Mass.-based Parexel is selling 1.6 mil. shares at $14 per share. The offering is being underwritten by William Blair & Co., Smith Barney and Adams, Harkness & Hill.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth